Imagine if rivals Boeing and Airbus teamed up on a new plane, or Microsoft and Apple built a computer.
That’s a bit like what Fred Hutchinson Cancer Research Center and Memorial Sloan-Kettering Cancer Center are attempting. Together, the two have launched a start-up, the goal being to develop a new cancer treatment that targets immune cells in the body and turns them into cancer-fighting soldiers.
The National Institutes of Health announced earlier this summer that it will reduce the number of chimpanzees used in scientific research and the Fish and Wildlife Service is considering classifying captive chimps, a category that includes these research chimps, as endangered species.
For many scientists, the use of chimps is unnecessary. But for those working towards a hepatitis C vaccine, there are few alternatives to chimps. David Hyde talks with University of Washington immunology professor Dr. Michael Gale Jr. about the future of hepatitis C research.